ConforMIS, Inc. (NASDAQ:CFMS) – Stock analysts at Oppenheimer Holdings lifted their FY2017 EPS estimates for ConforMIS in a report released on Thursday. Oppenheimer Holdings analyst S. Lichtman now expects that the medical instruments supplier will post earnings per share of ($1.25) for the year, up from their previous forecast of ($1.30). Oppenheimer Holdings currently has a “Buy” rating and a $6.00 target price on the stock. Oppenheimer Holdings also issued estimates for ConforMIS’s Q4 2017 earnings at ($0.28) EPS.

A number of other analysts also recently issued reports on the company. Zacks Investment Research upgraded ConforMIS from a “sell” rating to a “buy” rating and set a $4.75 price target for the company in a research report on Wednesday, July 12th. Canaccord Genuity lowered their price target on ConforMIS from $8.00 to $6.00 and set a “hold” rating for the company in a research report on Friday, August 4th. Deutsche Bank AG reiterated a “hold” rating and set a $5.00 target price (down from $6.00) on shares of ConforMIS in a research report on Friday, August 4th. BTIG Research reiterated a “hold” rating on shares of ConforMIS in a research report on Sunday, July 16th. Finally, ValuEngine upgraded ConforMIS from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. One investment analyst has rated the stock with a sell rating, four have given a hold rating and two have given a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $5.85.

COPYRIGHT VIOLATION NOTICE: This report was published by Daily Political and is the sole property of of Daily Political. If you are viewing this report on another website, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The original version of this report can be viewed at https://www.dailypolitical.com/2017/11/07/fy2017-eps-estimates-for-conformis-inc-cfms-lifted-by-oppenheimer-holdings.html.

ConforMIS (CFMS) opened at $3.66 on Monday. The company has a quick ratio of 6.11, a current ratio of 6.98 and a debt-to-equity ratio of 0.43.

ConforMIS (NASDAQ:CFMS) last posted its earnings results on Wednesday, November 1st. The medical instruments supplier reported ($0.29) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.03. ConforMIS had a negative net margin of 72.70% and a negative return on equity of 71.21%. The firm had revenue of $18.40 million during the quarter, compared to analyst estimates of $17.55 million. During the same period last year, the firm posted ($0.31) earnings per share. ConforMIS’s revenue for the quarter was down 1.3% compared to the same quarter last year.

Several hedge funds have recently added to or reduced their stakes in CFMS. Wells Fargo & Company MN raised its holdings in shares of ConforMIS by 1.8% in the first quarter. Wells Fargo & Company MN now owns 53,930 shares of the medical instruments supplier’s stock valued at $282,000 after acquiring an additional 935 shares in the last quarter. American International Group Inc. grew its stake in ConforMIS by 7.0% in the first quarter. American International Group Inc. now owns 22,009 shares of the medical instruments supplier’s stock valued at $115,000 after purchasing an additional 1,448 shares during the last quarter. Geode Capital Management LLC grew its stake in ConforMIS by 4.4% in the first quarter. Geode Capital Management LLC now owns 329,058 shares of the medical instruments supplier’s stock valued at $1,717,000 after purchasing an additional 13,731 shares during the last quarter. UBS Group AG grew its stake in ConforMIS by 53.0% in the first quarter. UBS Group AG now owns 269,551 shares of the medical instruments supplier’s stock valued at $1,407,000 after purchasing an additional 93,330 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. grew its stake in ConforMIS by 99.1% in the first quarter. Schwab Charles Investment Management Inc. now owns 111,500 shares of the medical instruments supplier’s stock valued at $583,000 after purchasing an additional 55,500 shares during the last quarter. Hedge funds and other institutional investors own 33.25% of the company’s stock.

About ConforMIS

ConforMIS, Inc is a medical technology company. The Company uses its iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants, which are individually sized and shaped, to fit each patient’s anatomy. The Company’s iFit technology platform is applicable to various joints.

Earnings History and Estimates for ConforMIS (NASDAQ:CFMS)

Receive News & Ratings for ConforMIS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConforMIS Inc. and related companies with MarketBeat.com's FREE daily email newsletter.